Hydroxychloroquine in rheumatic autoimmune disorders and beyond

EL Nirk, F Reggiori, M Mauthe - EMBO molecular medicine, 2020 - embopress.org
Initially used as antimalarial drugs, hydroxychloroquine (HCQ) and, to a lesser extent,
chloroquine (CQ) are currently being used to treat several diseases. Due to its cost …

[PDF][PDF] One year in review 2019: Sjögren's syndrome

G Cafaro, C Croia, OD Argyropoulou… - Clin Exp …, 2019 - clinexprheumatol.org
Primary Sjögren's syndrome (pSS) is a complex and heterogeneous disorder characterised
by a wide spectrum of glandular and extra-glandular features. Novel insights into disease …

EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies

M Ramos-Casals, P Brito-Zerón… - Annals of the …, 2020 - ard.bmj.com
The therapeutic management of Sjögren syndrome (SjS) has not changed substantially in
recent decades: treatment decisions remain challenging in clinical practice, without a …

[HTML][HTML] The role of regulatory T Cells in the onset and progression of primary Sjögren's syndrome

VG Blinova, VI Vasilyev, EB Rodionova, DD Zhdanov - Cells, 2023 - mdpi.com
Regulatory T cells (Tregs) play a key role in maintaining immune balance and regulating the
loss of self-tolerance mechanisms in various autoimmune diseases, including primary …

[HTML][HTML] Innate immunity and biological therapies for the treatment of Sjögren's syndrome

A Srivastava, HP Makarenkova - International journal of molecular …, 2020 - mdpi.com
Sjögren's syndrome (SS) is a systemic autoimmune disorder affecting approximately 3% of
the population in the United States. This disease has a female predilection and affects …

The role of epithelial cells in the immunopathogenesis of Sjögren's syndrome

Y Tang, Y Zhou, X Wang, N Che, J Tian… - Journal of Leukocyte …, 2024 - academic.oup.com
Sjögren's syndrome is a systemic autoimmune disease characterized by dysfunction of the
affected exocrine glands. Lymphocytic infiltration within the inflamed glands and aberrant B …

Sirolimus therapy restores the PD-1+ ICOS+ Tfh: CD45RA-Foxp3high activated Tfr cell balance in primary Sjögren's syndrome

Y Wang, H Guo, Z Liang, M Feng, Y Wu, Y Qin… - Molecular …, 2022 - Elsevier
Abstract Background Primary Sjögren's syndrome (pSS) is a common chronic autoimmune
disease characterized by lymphocytic infiltration of salivary and lacrimal glands. The current …

[HTML][HTML] Innate and adaptive cell populations driving inflammation in dry eye disease

JL Reyes, DT Vannan, B Eksteen, IJ Avelar… - Mediators of …, 2018 - hindawi.com
Dry eye disease (DED) is the most common ocular disease and affects millions of
individuals worldwide. DED encompasses a heterogeneous group of diseases that can be …

Expression of interleukin‐17 in primary Sjögren's syndrome and the correlation with disease severity: A systematic review and meta‐analysis

LW Zhang, PR Zhou, P Wei, X Cong… - Scandinavian Journal …, 2018 - Wiley Online Library
The aberrant expression of interleukin‐17 (IL‐17) has been reported in primary Sjögren's
syndrome (pSS). Abnormalities in IL‐17 can promote the production of pro‐inflammatory …

[HTML][HTML] Biological therapy in primary Sjögren's syndrome: Effect on salivary gland function and inflammation

F Chowdhury, A Tappuni, M Bombardieri - Frontiers in Medicine, 2021 - frontiersin.org
Primary Sjögren's syndrome (pSS) is a chronic, systemic autoimmune disease. It is the
second most common rheumatic autoimmune disorder, affecting 0.7% of European …